HOPE Therapeutics, a subsidiary of Wilmington, Del.-headquartered NRx Pharmaceuticals (Nasdaq: NRXP), has secured a $30 million deal to fund its planned acquisition of a network of psychiatric clinics focused on ketamine treatments. In a release, the Miami Beach, Fla., company said it had signed non-binding term sheets backed by a qualified lender to buy five clinics, located in the…